Cardiac Science warns customers about faulty AEDs
This article was originally published in Clinica
Cardiology technology specialist Cardiac Science has initiated a worldwide voluntary field corrective action for certain models of its Powerheart and CardioVive automated external defibrillators (AEDs), manufactured between August 2006 and March 2007. The Bothell, Washington-based company has received two complaints about a defect in the devices' software which causes it to go into ‘service required’ mode while attempting to provide defibrillation, thereby rendering it inoperable. Cardiac said that it is providing user-installable software update to affected customers and distributors. The firm expects this action to lead it to incur a pre-tax charge of $0.8-1m in the third quarter of 2008.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals